- Home
- IFRX vs BEAT Comparison
IFRX vs BEAT Comparison
Compare IFRX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- BEAT
- Stock Information
- Founded
- IFRX 2007
- BEAT 2015
- Country
- IFRX Germany
- BEAT United States
- Employees
- IFRX N/A
- BEAT N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- IFRX Health Care
- BEAT Technology
- Exchange
- IFRX Nasdaq
- BEAT Nasdaq
- Market Cap
- IFRX 53.5M
- BEAT 51.1M
- IPO Year
- IFRX 2017
- BEAT 2021
- Fundamental
- Price
- IFRX $0.87
- BEAT $1.25
- Analyst Decision
- IFRX Strong Buy
- BEAT Buy
- Analyst Count
- IFRX 4
- BEAT 1
- Target Price
- IFRX $7.75
- BEAT $8.00
- AVG Volume (30 Days)
- IFRX 359.0K
- BEAT 103.9K
- Earning Date
- IFRX 08-07-2025
- BEAT 08-13-2025
- Dividend Yield
- IFRX N/A
- BEAT N/A
- EPS Growth
- IFRX N/A
- BEAT N/A
- EPS
- IFRX N/A
- BEAT N/A
- Revenue
- IFRX $140,242.00
- BEAT N/A
- Revenue This Year
- IFRX N/A
- BEAT N/A
- Revenue Next Year
- IFRX $1,276.37
- BEAT N/A
- P/E Ratio
- IFRX N/A
- BEAT N/A
- Revenue Growth
- IFRX 30.90
- BEAT N/A
- 52 Week Low
- IFRX $0.71
- BEAT $1.17
- 52 Week High
- IFRX $2.82
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- IFRX 45.31
- BEAT 39.88
- Support Level
- IFRX $0.82
- BEAT $1.20
- Resistance Level
- IFRX $0.93
- BEAT $1.35
- Average True Range (ATR)
- IFRX 0.06
- BEAT 0.09
- MACD
- IFRX 0.02
- BEAT 0.01
- Stochastic Oscillator
- IFRX 33.94
- BEAT 60.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.